Skip to main content
logo
RAPT Therapeutics, Inc. (RAPT)
Mar 3, 2026 - RAPT was delisted (reason: acquired by GSK)
58.02
0.00 (0.00%)
Inactive · Last trade price on Mar 2, 2026

RAPT Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
---1.533.815.04
Revenue Growth
----59.95%-24.38%-
Gross Profit
---1.533.815.04
Operating Income
-112.64-136.1-127.06-85.8-69.21-53.21
Net Income
-105.64-129.87-116.8-83.84-69.2-52.89
Earnings Per Share
-11.06-25.52-24.40-20.64-20.24-17.52
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
157.34231.06158.86249.07189.65111.51
Total Debt
2.64.496.918.9900
Net Cash (Debt)
154.75226.56151.96240.08189.65111.51
Net Cash Growth
66.78%49.10%-36.71%26.59%70.08%44.10%
Net Cash Per Share
7.1444.4731.7159.0255.3936.96

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-86.58-83.3-97.05-70.77-61.03-40.49
Capital Expenditures
-0.08-0.12-1.13-0.85-0.76-0.4
Free Cash Flow
-86.66-83.42-98.17-71.62-61.78-40.89
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
---100.00%100.00%100.00%
Operating Margin
----5618.53%-1815.08%-1055.41%
Pretax Margin
----5490.37%-1814.95%-1029.39%
Profit Margin
----5490.37%-1814.95%-1049.03%
FCF Margin
----4689.98%-1620.27%-810.97%

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJul '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
---444.16284.7097.04